Expression of phenotypic markers and cytotoxic molecules
| . | ALK+ALCL (n = 83) . | ALK− ALCL (n = 60) . | P value . |
|---|---|---|---|
| CD56 | 13/81 (16%) | 12/59 (20%) | .51 |
| CD30 | 81/83 (98%) | 60/60 (100%) | .34 |
| CD15 | 0/78 | 11/55 (20%) | < .0001 |
| CD20 | 0/83 | 0/60 | 1.00 |
| CD45RO | 29/76 (38%) | 21/48 (44%) | .54 |
| CD43 | 34/68 (50%) | 24/46 (52%) | .82 |
| CD3 | 31/74 (42%) | 26/50 (52%) | .27 |
| CD4 | 34/74 (46%) | 18/46 (39%) | .46 |
| CD8 | 10/73 (14%) | 6/47 (13%) | .88 |
| EMA | 80/83 (96%) | 26/55 (47%) | < .0001 |
| BCL2 | 0/45 | 14/27 (52%) | < .0001 |
| TIA-1 | 59/75 (79%) | 23/54 (43%) | < .0001 |
| Granzyme B | 53/81 (65%) | 24/57 (42%) | .007 |
| EBERs | 0/80 | 12/58 (21%) | < .0001 |
| . | ALK+ALCL (n = 83) . | ALK− ALCL (n = 60) . | P value . |
|---|---|---|---|
| CD56 | 13/81 (16%) | 12/59 (20%) | .51 |
| CD30 | 81/83 (98%) | 60/60 (100%) | .34 |
| CD15 | 0/78 | 11/55 (20%) | < .0001 |
| CD20 | 0/83 | 0/60 | 1.00 |
| CD45RO | 29/76 (38%) | 21/48 (44%) | .54 |
| CD43 | 34/68 (50%) | 24/46 (52%) | .82 |
| CD3 | 31/74 (42%) | 26/50 (52%) | .27 |
| CD4 | 34/74 (46%) | 18/46 (39%) | .46 |
| CD8 | 10/73 (14%) | 6/47 (13%) | .88 |
| EMA | 80/83 (96%) | 26/55 (47%) | < .0001 |
| BCL2 | 0/45 | 14/27 (52%) | < .0001 |
| TIA-1 | 59/75 (79%) | 23/54 (43%) | < .0001 |
| Granzyme B | 53/81 (65%) | 24/57 (42%) | .007 |
| EBERs | 0/80 | 12/58 (21%) | < .0001 |
EBER indicates Epstein-Barr–encoded small RNA; EMA, epithelial membrane antigen.